Im I Na

Summary

Affiliation: Korea Cancer Center Hospital
Country: Korea

Publications

  1. ncbi A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma
    Keun-Wook Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Korea
    J Korean Med Sci 20:598-62. 2005
  2. ncbi CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
    J Cancer Res Ther 8:247-53. 2012
  3. ncbi Significance of smoking history and FDG uptake for pathological N2 staging in clinical N2-negative non-small-cell lung cancer
    I I Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Ann Oncol 22:2068-72. 2011
  4. ncbi 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 215 4, Gongneung dong, Nowon Gu, Seoul, 139 706, Republic of Korea
    Lung Cancer 67:76-80. 2010
  5. ncbi A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, Republic of Korea
    Eur J Cancer 44:2411-7. 2008
  6. ncbi EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil
    Im Il Na
    Department of Internal Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, 215 4, Gongneung dong, Nowon Gu, Seoul, 139 706, Korea
    Eur J Cancer 43:520-6. 2007
  7. ncbi Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective study
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
    Lung Cancer 60:69-74. 2008
  8. ncbi Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia
    Im I Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Eur J Haematol 79:1-7. 2007
  9. ncbi 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, Korea
    Clin Cancer Res 14:2036-41. 2008
  10. ncbi The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, South Korea
    Lung Cancer 57:96-102. 2007

Collaborators

  • Y H Park
  • Du Hwan Choe
  • Keunchil Park
  • Jong Ho Park
  • Seung Sook Lee
  • Myung Ju Ahn
  • Soo Mee Bang
  • Sung Hyun Yang
  • Jae Cheol Lee
  • Jin Kyung Rho
  • Baek Yeol Ryoo
  • Cheol Hyeon Kim
  • Hye Jin Kang
  • Baek-Yeol Ryoo
  • Hye Ryoun Kim
  • Dae Ho Lee
  • Yun Jung Choi
  • Jin Kyung Lee
  • Byung Hyun Byun
  • Jang Hyun Cho
  • Keun-Wook Lee
  • Sung Hyeon Yang
  • Sang We Kim
  • Yoon Hee Choi
  • Cheolwon Suh
  • Min Soo Kang
  • Jin Seok Ahn
  • Jung Shin Lee
  • Young Do Yoo
  • Gi Jeong Cheon
  • Sang Moo Lim
  • Chang Woon Choi
  • Kyeong Min Kim
  • Chul Won Jung
  • Kihyun Kim
  • Sung Yong Oh
  • Sung In Cho
  • Jae Soo Koh
  • Young H Ko
  • Won Seog Kim
  • Jee Hyun Kim
  • Eun Kee Song
  • Jong Seok Lee
  • Jae Hoon Lee
  • Tak Yun
  • Noe Kyeong Kim
  • Seonyang Park
  • Hyunchoon Shin
  • Sung-Soo Yoon
  • Byoung Kook Kim

Detail Information

Publications21

  1. ncbi A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma
    Keun-Wook Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Korea
    J Korean Med Sci 20:598-62. 2005
    ..Overall, bortezomib seems to be effective and feasible. Conduction of larger clinical studies on Korean patients is necessary to characterize clinical efficacy and safety of bortezomib more precisely...
  2. ncbi CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
    J Cancer Res Ther 8:247-53. 2012
    ..We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with non-small-cell lung cancer (NSCLC) treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib...
  3. ncbi Significance of smoking history and FDG uptake for pathological N2 staging in clinical N2-negative non-small-cell lung cancer
    I I Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Ann Oncol 22:2068-72. 2011
    ....
  4. ncbi 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 215 4, Gongneung dong, Nowon Gu, Seoul, 139 706, Republic of Korea
    Lung Cancer 67:76-80. 2010
    ..025). (18)F-FDG uptake was associated with the presence of EGFR mutation. These results extrapolate that (18)F-FDG uptake might be helpful to discriminate patients who harbor EGFR mutations, especially when a genetic test is not feasible...
  5. ncbi A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, Republic of Korea
    Eur J Cancer 44:2411-7. 2008
    ..153). Although this diagnostic model should be validated through further studies, our data suggest that the number of risk factors might be a useful tool to identify silent brain metastases in patients with NSCLC...
  6. ncbi EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil
    Im Il Na
    Department of Internal Medicine, Korea Cancer Centre Hospital, Korea Institute of Radiological and Medical Sciences, 215 4, Gongneung dong, Nowon Gu, Seoul, 139 706, Korea
    Eur J Cancer 43:520-6. 2007
    ..Clinical features of lung cancer patients with EGFR mutations were not observed in HNSCC. A further study will be needed to confirm these results...
  7. ncbi Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: a retrospective study
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
    Lung Cancer 60:69-74. 2008
    ..053). These results suggest that FDG uptake by the N2 node may predict survival of patients with stage IIIA N2 NSCLC...
  8. ncbi Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia
    Im I Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Eur J Haematol 79:1-7. 2007
    ..001). Current study suggests that prognostic factors for NHL may be useful to predict the outcome of NTCL but the model should take LDH level and the prognostic weight of each factor into account...
  9. ncbi 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, Korea
    Clin Cancer Res 14:2036-41. 2008
    ..To evaluate response and survival according to (18)F-fluoro-2-deoxy-glucose uptake at presentation in patients with gefitinib-treated non-small cell lung cancer...
  10. ncbi The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, South Korea
    Lung Cancer 57:96-102. 2007
    ..004). There was no significant correlation between the expressions of p21 and p53. Survival outcomes in the patients with resected NSCLC may be correlated with the presence of a p21 expression and EGFR mutations...
  11. ncbi Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 215 4 Gongneung dong, Nowon Gu, Seoul, Korea
    J Korean Med Sci 22:393-9. 2007
    ..742). Patients with an EGFR mutation in exons 18-19 had better survival than patients without such mutation. Subtypes of EGFR mutations may be prognostic factors in patients undergoing curative resection...
  12. ncbi Synchronous multiple primary lung cancers with different response to gefitinib
    Baek-Yeol Ryoo
    Department of Internal Medicine, Korea Cancer Center Hospital, 215-4, Gongneung-dong, Nowon-gu, Seoul, 139-706, Republic of Korea
    Lung Cancer 53:245-8. 2006
    ..These synchronous tumors with different location, histology, status of EGFR-TK mutations and response to chemotherapy might be caused by different molecular pathogenesis...
  13. ncbi Clinical significance of 18F-FDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study
    Byung Hyun Byun
    Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
    Ann Nucl Med 22:645-51. 2008
    ....
  14. ncbi Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma
    Yeon H Park
    Department of Hematology-Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea
    Eur J Haematol 77:304-8. 2006
    ..CONCLUSIONS: The proposed new prognostic model for HG-PGL demonstrated a balanced distribution of patients into four groups with good prognostic capacity...
  15. ncbi Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
    Jin Kyung Rho
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, Seoul 139 706, Republic of Korea
    Lung Cancer 63:219-26. 2009
    ..Conversely, this was reversed through the removal of TGF-beta1. In conclusion, induction of EMT may contribute to the decreased efficacy of therapy in primary and acquired resistance to gefitinib...
  16. ncbi The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients
    Hye Ryoun Kim
    Department of Internal Medicine, Korea Cancer Center Hospital, 215 4, Gongneung dong, Nowon Gu, Seoul, 139 706, Korea
    J Cancer Res Clin Oncol 136:547-52. 2010
    ..This study was undertaken to evaluate the clinical benefits of pemetrexed and to identify patient characteristics that predict response to pemetrexed...
  17. ncbi The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors
    Jin Kyung Rho
    Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Mol Cancer Res 7:1736-43. 2009
    ..Accordingly, the present study suggests that MET activation caused by factors other than MET gene amplification is not a suitable surrogate marker of resistance to EGFR-TKIs...
  18. ncbi Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer
    Im Il Na
    Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, 215 4, Gongneung dong, Nowon Gu, Seoul 139 706, Republic of Korea
    Lung Cancer 68:295-8. 2010
    ..When molecular tests are not feasible, our results might help physician to select a beneficial subgroup in female patients...
  19. ncbi High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: a clinicopathologic study of 18 cases in the Korean population
    Jang Hyun Cho
    Department of Internal Medicine, Korea Institute of Radiological and Medical Science, Nowon-Ku, Seoul, Korea
    Leuk Lymphoma 47:2128-31. 2006
    ..All patients achieved complete remission. All 18 patients were alive with a median follow-up period of 55 months. The prognosis of patients with primary thyroid lymphoma appears to be favourable...
  20. ncbi Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer
    Dae Ho Lee
    Department of Oncology, Asan Medical Center, University of UIsan College of Medicine, Seoul, Korea
    Cancer 116:132-6. 2010
    ..The objective of this study was to investigate the efficacy of belotecan, a new camptothecin analog, combined with cisplatin for the treatment of chemotherapy-naive patients with extensive-disease small cell lung cancer (ED SCLC)...
  21. ncbi Primary gastric lymphoma of T-cell origin: clinicopathologic features and treatment outcome
    Yeon Hee Park
    Department of Hematology Oncology, Korea Institute of Radiological and Medical Sciences, Nowon Ku, Seoul, Republic of Korea
    Leuk Res 30:1253-8. 2006
    ..This study showed that the incidence of this subtype of T-cell gastric lymphoma was very rare, and had poor prognosis...